Knowing When to Call It Quits in Drug Development and Healthcare Innovations

The drug development process is costly, time consuming and laden with risk—with only 1% of drugs making it from pre-clinical all the way to market, according to Pharma Intelligence . To beat these odds, life sciences leaders must know when to continue funding a promising, new product and when to call it quits. Tune in for insights into: Why a “fast to failure” mentality is key to a successful development pipeline How leaders can redivert organizational resources after ending a program Why drug development failures can ultimately lead to positive outcomes

You can listen to Knowing When to Call It Quits in Drug Development and Healthcare Innovations online on Radio and Podcast. Open the player on this page to stream the available audio.

Knowing When to Call It Quits in Drug Development and Healthcare Innovations is an episode from BDO's Health & Life Sciences Rx Podcast by Olivia Clement.

This episode is 34:28 long.

This episode was published on May 22, 2020.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from BDO's Health & Life Sciences Rx Podcast when more episodes are available from the podcast feed.